Back to results
US 12,612,458 B2Granted
Anti-αβTCR antibody
AssigneeGenzyme Corporation
InventorsDaniel Snell, Andreas Menrad, Gina Lacorcia, Srinivas Shankara, Huawei Qiu, Clark Pan, Benjamin Kebble
Life of this patent
Estimating the term…
Abstract
The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.
Claims19
A nucleic acid encoding at least a humanized monoclonal antibody specific for the human αβTCR/CD3 complex
- comprising a humanized monoclonal antibody which comprises a heavy chain variable region selected from the heavy chains comprising the amino acid sequences set forth in SEQ ID NO:
- 15 and SEQ ID NO:
- 16, and a light chain variable region comprising the amino acid sequence as set forth in SEQ ID NO 14.
A method of making an antibody comprising:
- culturing a host cell under conditions to produce a humanized monoclonal antibody specific for the human αßTCR/CD3 complex, and
- recovering the antibody,
- wherein the host cell is introduced with a nucleic acid comprising a heavy chain variable region comprising the amino acid sequences set forth in SEQ ID NO. 15 and a light chain variable region comprising the amino acid sequence as set forth in SEQ ID NO. 14.
A method of making an antibody comprising:
- culturing a recombinant host cell under conditions to produce a humanized monoclonal antibody specific for the human αßTCR/CD3 complex, and
- recovering the antibody,
- wherein the host cell is introduced with a nucleic acid comprising a heavy chain variable region comprising the amino acid sequences set forth in SEQ ID NO:
- 16 and a light chain variable region comprising the amino acid sequence as set forth in SEQ ID NO. 14.
1 more element
Dependencies are inferred from the claim text.